Table 1.
Baseline demographic and clinical characteristics at diagnosis
| Pre era |
Post era |
|||||||
|---|---|---|---|---|---|---|---|---|
| Total n = 2998 n (%) |
NHW n = 2566 n (%) |
NHB n = 221 n (%) |
Hispanic n = 211 n (%) |
Total n = 2098 n (%) |
NHW n = 1809 n (%) |
NHB n = 162 n (%) |
Hispanic n = 127 n (%) |
|
| Median age, y | 68.5 | 69.0 | 64.0 | 60.0 | 71.0 | 72.0 | 68.5 | 65.0 |
| Sex, M | 1734 (58) | 1518 (59) | 107 (48) | 109 (52) | 1187 (57) | 1061 (59) | 66 (41) | 60 (47) |
| Payer category | ||||||||
| Public | 653 (22) | 589 (23) | 28 (3) | 36 (17) | 520 (25) | 453 (25) | 43 (27) | 24 (19) |
| Private | 1413 (47) | 1234 (48) | 98 (44) | 81 (38) | 1063 (51) | 938 (52) | 76 (47) | 49 (39) |
| Other | 269 (9) | 221 (9) | 19 (9) | 29 (14) | 220 (11) | 183 (10) | 17 (11) | 20 (16) |
| No/unknown | 663 (22) | 522 (20) | 76 (34) | 65 (31) | 295 (14) | 235 (13) | 26 (16) | 34 (27) |
| Practice | n = 2992 | n = 2561 | n = 221 | n = 210 | n = 2096 | n = 1807 | n = 162 | n = 127 |
| Community | 1843 (62) | 1578 (62) | 130 (59) | 134 (64) | 1225 (58) | 1060 (59) | 91 (56) | 74 (58) |
| SES index∗,† | n = 2698 | n = 2315 | n = 196 | n = 187 | n = 1909 | n = 1646 | n = 147 | n = 117 |
| 1 | 331 (12) | 222 (10) | 67 (34) | 42 (23) | 244 (13) | 151 (9) | 53 (36) | 40 (34) |
| 2 | 512 (19) | 414 (18) | 48 (25) | 50 (27) | 322 (17) | 269 (16) | 34 (23) | 19 (16) |
| 3 | 606 (23) | 524 (23) | 34 (17) | 48 (26) | 419 (22) | 368 (22) | 23 (16) | 28 (24) |
| 4 | 653 (24) | 594 (26) | 27 (14) | 32 (17) | 472 (25) | 439 (27) | 18 (12) | 15 (13) |
| 5 | 596 (22) | 561 (24) | 20 (10) | 15 (8) | 452 (24) | 418 (25) | 19 (13) | 15 (13) |
| HCT-CI27† | n = 2704 | n = 2339 | n = 199 | n = 166 | n = 1988 | n = 1723 | n = 154 | n = 111 |
| 0 | 1268 (47) | 1085 (46) | 100 (50) | 83 (50) | 706 (36) | 599 (35) | 47 (31) | 60 (54) |
| 1-2 | 601 (22) | 523 (22) | 36 (18) | 42 (25) | 492 (25) | 440 (26) | 32 (21) | 20 (18) |
| ≥3 | 835 (31) | 731 (31) | 63 (32) | 41 (25) | 790 (40) | 684 (40) | 75 (49) | 31 (28) |
| ELN 2017† | n = 2505 | n = 2150 | n = 177 | n = 178 | n = 1781 | n = 1535 | n = 138 | n = 108 |
| Favorable | 338 (14) | 293 (14) | 20 (11) | 25 (14) | 243 (14) | 205 (13) | 20 (15) | 18 (17) |
| Intermediate | 1114 (45) | 959 (45) | 74 (42) | 81 (46) | 721 (41) | 608 (40) | 66 (48) | 47 (44) |
| Adverse | 1053 (42) | 898 (42) | 83 (47) | 72 (40) | 817 (46) | 722 (47) | 52 (38) | 43 (40) |
| s-AML, yes | 1039 (35) | 922 (36) | 64 (29) | 53 (25) | 770 (37) | 687 (38) | 45 (28) | 38 (30) |
| Treatment-related AML, yes | 251 (8) | 200 (8) | 31 (14) | 20 (10) | 217 (10) | 188 (10) | 22 (14) | 7 (6) |
| Cytogenetics‡ | n = 2523 | n = 2166 | n = 179 | n = 178 | n = 1825 | n = 1576 | n = 141 | n = 108 |
| t(8;21) | 125 (5) | 91 (4) | 16 (9) | 18 (10) | 82 (5) | 61 (4) | 13 (9) | 8 (7) |
| inv(16) | 131 (5) | 109 (5) | 13 (7) | 9 (5) | 70 (4) | 53 (3) | 11 (8) | 6 (6) |
| del(7) | 437 (17) | 383 (18) | 28 (16) | 26 (15) | 329 (18) | 301 (19) | 15 (11) | 13 (12) |
| del(17) | 191 (8) | 165 (8) | 17 (10) | 9 (5) | 134 (7) | 119 (8) | 10 (7) | 5 (5) |
| High-risk mutations‡ | n = 1991 | n = 1720 | n = 137 | n = 134 | n = 1740 | n = 1511 | n = 132 | n = 97 |
| TP53 | 133 (7) | 121 (7) | 4 (3) | 8 (6) | 243 (14) | 216 (14) | 16 (12) | 11 (11) |
| RUNX1 | 155 (8) | 130 (8) | 13 (10) | 12 (9) | 234 (13) | 207 (14) | 16 (12) | 11 (11) |
| ASXL1 | 149 (8) | 126 (7) | 12 (9) | 11 (8) | 232 (13) | 206 (14) | 15 (11) | 11 (11) |
| KRAS | 47 (2) | 38 (2) | 5 (4) | 4 (3) | 73 (4) | 65 (4) | 6 (5) | 2 (2) |
| NRAS | 124 (6) | 103 (6) | 14 (10) | 7 (5) | 171 (10) | 138 (9) | 18 (14) | 15 (16) |
| Induction intensity, high | 1628 (58) | 1341 (56) | 139 (67) | 148 (74) | 755 (37) | 618 (35) | 71 (45) | 66 (53) |
HCT-CI, hematopoietic cell transplantation–specific comorbidity index; M, male.
∗
SES index, Tier 1 being the lowest level and Tier 5 being the highest.
†
Among patients whose information was available.
‡
Among patients tested.